The outcomes propose a variety of novel targets for intervening in cholangiocarcinoma growth, encompassing gram-negative intestinal bacteria, TLR4, CXCL1, CXCR2, and MDSCs themselves. This evidence concerns the gene TLR4 and cholangiocarcinoma.